Clinical characteristics of 50466 patients with 2019-nCoV infection

Abstract

Objective: We aim to summarize reliable evidences of evidence-based medicine for the treatment and prevention of the 2019 novel coronavirus (2019-nCoV) by analyzing all the published studies on the clinical characteristics of patients with 2019-nCoV. Methods: PubMed, Cochrane Library, Embase, and other databases were searched. Several studies on the clinical characteristics of 2019-nCoV infection were collected for Meta-analysis.Results: Ten studies were included in Meta-analysis, including a total number of 50466 patients with 2019-nCoV infection. Meta-analysis shows that, among these patients, the incidence of fever was 89.1%, the incidence of cough was 72.2%, and the incidence of muscle soreness or fatigue was 42.5%. The incidence of acute respiratory distress syndrome (ARDS) was 14.8%, the incidence of abnormal chest computer tomography (CT) was 96.6%, the percentage of severe cases in all infected cases was 18.1%, and the case fatality rate of patients with 2019-nCoV infection was 4.3%. Conclusion: Fever and cough are the most common symptoms in patients with 2019-nCoV infection, and most of these patients have abnormal chest CT examination. Several people have muscle soreness or fatigue as well as ARDS. Diarrhea, hemoptysis, headache, sore throat, shock, and other symptoms only occur in a small number of patients. The case fatality rate of patients with 2019-nCoV infection is lower than that of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

“…Comparing their findings [58] with ours, they found fever in 89.8% (95%CI 81.8-94.5%) of patients, this SR found 88.7% (95%CI 84.5-92.9%), but we assessed differences, as mentioned above, between adults and children, and they did not. For cough, based on the 95%CI, there were not significant differences too, between that SR and the current, 72 [58], we were able to do it for eight of the studies included in this systematic review. Both reviews are clear and consistent in that more than 80% of the patients presented with fever, more than half with cough, and more than a third with fatigue.…”

“…After the development of this systematic review (SR), and even availability on a preprint server, online Feb. 25,2020 (http://dx.doi.org/10.20944/preprints202002.0378.v1); a brief systematic review and meta-analysis, only addressing few variables, such as fever, cough, muscle soreness or fatigue, ARDS, abnormal chest CT, patients in critical condition and death of patients with COVID-19, was published (Feb. 28, 2020) [58]. This review was based on ten studies, using a random effect model, as we did.…”

Deep learning for predicting COVID-19 malignant progression

“…The risk factors mentioned above are all in accordance with the results from observation studies [22][23][24][25][26] . Fibrosis on CT imaging is reported to be closely associated with the late outcome of COVID-19 pneumonia 27,28 . However, our study depicted the early presence of fibrosis on CT imaging is a protective factor for malignant progression, which might reflect early absorption of inflammation and the occurrence of the repair stage.…”

Extracellular superoxide dismutase, a molecular transducer of health benefits of exercise

“…These findings strongly support that enhanced EcSOD expression from skeletal muscle or other tissues/organ, which can be redistributed to the lung tissue, could be a viable preventative/therapeutic measures in reducing the risk and severity of ALI/ARDS. Considering the current outbreak of the 2019 Novel Corona virus infection (COVID- 19), which is an infectious disease that leads to progressive ALI/ARDS in many patients (6,103,107,113), it is conceivable that regular exercise might be effective in preventing while EcSOD gene/protein therapy might be effective in treating ALI/ARDS under the condition of COVID-19 infection.…”